Johnson & Johnson (JNJ.US) / Legend Biotech (LEGN.US) CAR-T therapy has achieved positive results in phase III.

According to the news from the Securities Times app, on July 3, Johnson & Johnson (JNJ.US) and Legend Biotech (LEGN.US) jointly announced the positive results of the planned second interim analysis of the Phase 3 CARTITUDE-4 study. The study evaluated the chimeric antigen receptor (CAR) T cell therapy Carvykti jointly developed by the two companies, compared to standard therapy, for the treatment of patients with relapsed or refractory multiple myeloma (MM) who are resistant to lenalidomide after 1st-line treatment. The interim analysis showed that compared with standard therapy, patients treated with Carvykti had a longer overall survival.

Zhitong Finance10:03

Express News | Johnson & Johnson has received approval from the US Food and Drug Administration and the European Commission for SIRTURO (bedaquiline), a pharmaceutical.

Breakings07:48

Express News | Johnson & Johnson Receives Approval From U.S. FDA and European Commission for Sirturo® (Bedaquiline)

Breakings07:46

JNJ Should Rally Soon or See 3 Swings Higher at Least

Johnson & Johnson (JNJ) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue.

FXStreet00:46

J&J Says Carvykti Beat Standard Drugs in Late-stage Blood Cancer Trial

Seeking AlphaJul 2 20:23

Johnson & Johnson Says Interim Analysis of Blood Cancer Therapy Study Show Promise

Johnson & Johnson (JNJ) said on Tuesday interim analysis of the Phase 3 study of its experimental therapy, Carvykti, to treat certain patients with a type of blood cancer showed a statistically signif

MT NewswiresJul 2 19:56